Top Clinical Trials Startups in 2026

SiteRx is a data security control and quality system to ensure that data remains secure, reliable, and HIPAA-compliant. The products provide assistance in inpatient trials with the assistance of AI-based technology. They are specialized in healthcare information technology, artificial intelligence, natural language processing, machine learning, clinical trials, patient recruitment, and neurology.

Crescendo Health is an innovative digital health company whose mission is to accelerate clinical trials and medical innovation. Crescendo Health is transforming the way patient health data is collected and used to advance clinical research. Leveraging many of the same transformative technologies that have revolutionized patient care, Crescendo Health builds relationships with patients and curates the data for trial sponsors to have a more comprehensive and longitudinal view of patient health. Founded by veteran healthcare executives from Datavant and Grand Rounds, the Crescendo Health team includes leaders from across research, technology, academic and provider communities. The company was founded in 2021 and is backed by leading institutional and angel investors. The time has come to build a new generation of clinical trials that makes use of real world health data, so that new treatments can be developed quickly for those in need and trial evidence reflects the diversity of our population.

IonPath is a Stanford University spin-out with a vision to transform clinical pathology and tumor imaging, a $10B+ market, with the company's novel, highly multi-parametric imaging technology, Multiplexed Ion Beam Imaging (MIBI). IonPath's MIBI is a step-change improvement over the current leading tumor imaging method, immunohistochemistry (IHC). MIBI enables researchers, pathologists, and clinicians to quantitatively analyze and visually display the complex interactions among cancer tumor cells, proteins, antibodies, T-cells, and other relevant features on cells' surfaces and interiors. Understanding these biological players and their interactions should substantially improve cancer research and drug discovery, produce novel diagnostics, and transform the study of disease mechanisms such as cancer ("pathology"). IonPath will develop and commercialize services, instruments, reagents, and ultimately diagnostic tests based on MIBI technology.

Saama is the #1 AI-driven Intelligent Clinical Cloud company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Today, over 50 biotech companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform on more than 1,500 studies, including many of the top 20 pharmaceutical companies. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. Discover more at saama.com and follow Saama @SaamaTechInc.

There is a big gap between the innovations humanity has already come up with and what is available to patients for diagnostics and treatment. This gap is largely caused by a high degree of regulation which is needed to ensure patient safety. At Platomics, it is our mission to cut the gap between the technology humanity has at its disposal and what we can offer to patients - from currently up to 10 years down to 2 years and less.

Prancer The world’s first 100% configurable Randomization and Trial Supply Management Solution Your RTSM should adapt as trials evolve, without disruption. The complexity of today’s trials is inadequately supported by traditional RTSM solutions, typically requiring custom coding to deliver system changes – costing you both time and resources. As trial complexity continues to increase, shouldn’t your system keep up? Prancer brings both speed and flexibility to clinical trials, enabling your trial to ebb and flow as needs change, all while offering exceptional quality and performance.

Dyania’s mission is to deploy their medically specialized and proprietary Synapsis AI to automate manual chart review, one of the most inefficient and time-consuming processes in modern healthcare, thereby empowering clinicians to deliver optimal care, precisely when patients need it. Dyania’s system is being used at large healthcare systems to unlock enterprise-wide clinical trial pre-screening, run automated chart review for observational studies, and automate complex registry reporting, dramatically reducing manual workloads and ensuring more accurate and timely patient care.

Intake AI is building the agentic intelligence layer for clinical trials. Our platform provides clinical research sites with a unified, queryable data source, and we deploy agents to automate some of their most tedious data workflows. These include data transfers, query resolution, document creation, and data security/warehousing.

Atreo has revolutionized the client experience by harnessing industry expertise and modern technologies to thoughtfully create the next-generation RTSM platform. The Atreo team, comprised of RTSM SMEs and Advisors, has addressed all the pain points common of legacy RTSM deployments, offering novel advantages with specific emphasis on: • Speed: 1 - 2 week RTSM build from Kickoff to Go-Live - Atreo’s revolutionary System Design Experience allows systems to be built within 1-2 weeks, including system specifications • Rapid Prototyping: Preview your RTSM, tailored to your protocol, at Bid Defense & throughout System Design Experience • Quality Quantified: Atreo’s modern architecture and process provides unmatched and quantifiable quality advantages through a hybrid of modern testing practices, allowing for unmatched testing coverage and time savings • Agility: Atreo RTSM offers unmatched configurability and Post Go Live System agility, including the majority of system changes at no cost Atreo's mantra is Time Better Spent. Please reach out to our team to learn how our mantra will become your reality and expectation when partnering with Atreo.